NanoVibronix (NAOV) 10-Q/A 24 Aug 20 2020 Q2 Quarterly report (amended) Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2020	Aug. 18, 2020
Cover [Abstract]
Entity Registrant Name	NanoVibronix, Inc.
Entity Central Index Key	0001326706
Document Type	10-Q/A
Document Period End Date	Jun. 30, 2020
Amendment Flag	true
Amendment Description	NanoVibronix, Inc., (the "Company") is filing this Amendment No. 1 on Form 10-Q/A ("Amendment No. 1") to amend its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2020, which was filed with the Securities and Exchange Commission ("SEC"), on August 19, 2020 (the "Original Filing"). The Company is filing this Amendment No. 1 to (i) clarify the description of the cash restricted pursuant to a court order in Note 10 - Commitments and Contingencies to Condensed Consolidated Financial Statements and Part II, Item 1. Legal Proceedings, (ii) include a risk factor regarding the Company's breach of the court order due to the Company's failure to maintain a sufficient amount of cash held in the Company's bank accounts, (iii) amend Note 2 - Liquidity and Plan of Operations and Note 5 - Notes Payable to Condensed Consolidated Financial Statements and Part I, Item 2. Management's Discussions and Analysis of Financial Condition and Results of Operations to include disclosure that as of June 30, 2020, there was no event of default or violation of a covenant in outstanding notes resulting from the breach of the court order, and (iv) furnish XBRL Exhibits 101 in accordance with Rule 405 of Regulation S-T, which provides the financial statements and related notes from the Form 10-Q formatted in XBRL (eXtensible Business Reporting Language). In accordance with Rule 12b-15 under the Securities Exchange Act of 1934, as amended, this Amendment No. 1 also includes currently dated certifications from the Company's principal executive officer and principal financial officer as required by Sections 302 and 906 of the Sarbanes-Oxley Act of 2002. Accordingly, the Exhibit Index in Part II, Item 6. of the Original Filing is also being amended to reflect the filing of the new certifications. Other than the revisions of the disclosures as discussed above and expressly set forth herein, this Amendment No. 1 continues to speak as of the filing date of the Original Filing and does not reflect any events that may have occurred subsequent to such date.
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		4,988,764
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2020

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents		$ 1,338
Restricted cash	202
Trade receivables	257	111
Other accounts receivable and prepaid expenses	158	268
Inventory	148	121
Total current assets	765	1,838
Non-current assets:
Fixed assets, net	3	4
Other assets	32
Severance pay fund	209	194
Total non-current assets	244	198
Total assets	1,009	2,036
Current liabilities:
Trade payables	136	129
Other accounts payable and accrued expenses	189	280
Common stock payable	844
Notes payable to a related party, net of discount of $123	77
Notes payable, current	4
Total current liabilities	1,250	409
Non-current liabilities:
Accrued severance pay	279	279
Deferred licensing income	226
Notes payable, non-current	38
Total liabilities	1,793	688
Commitments and contingencies (Note 10)
Stockholders' equity:
Common stock of $0.001 par value - Authorized: 20,000,000 shares at June 30, 2020 and December 31, 2019; Issued and outstanding: 4,313,764 and 4,203,764 shares at June 30, 2020 and December 31, 2019, respectively	5	5
Additional paid in capital	39,935	39,669
Accumulated deficit	(40,728)	(38,330)
Total stockholders' equity	(784)	1,348
Total liabilities and stockholders' equity	1,009	2,036
Series C Preferred Stock [Member]
Stockholders' equity:
Preferred stock value	2	2
Total stockholders' equity	2	2
Series D Preferred Stock [Member]
Stockholders' equity:
Preferred stock value
Total stockholders' equity
Series E Preferred Stock [Member]
Stockholders' equity:
Preferred stock value	2	2
Total stockholders' equity	$ 2	$ 2

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Discounts on notes payable current	$ 123	$ 123
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	20,000,000	20,000,000
Common stock, shares issued	4,313,764	4,203,764
Common stock, shares outstanding	4,313,764	4,203,764
Series C Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	3,000,000	3,000,000
Preferred stock, shares issued	2,993,142	2,733,142
Preferred stock, shares outstanding	2,993,142	2,733,142
Series D Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	506	506
Preferred stock, shares issued	304	304
Preferred stock, shares outstanding	304	304
Series E Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	1,999,494	1,999,494
Preferred stock, shares issued	1,715,000	1,825,000
Preferred stock, shares outstanding	1,715,000	1,825,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Income Statement [Abstract]
Revenues	$ 269	$ 263	$ 383	$ 342
Cost of revenues	231	56	294	82
Gross profit	38	207	89	260
Operating expenses:
Research and development	16	150	63	302
Selling and marketing	180	271	434	592
General and administrative	1,310	682	1,967	2,485
Total operating expenses	1,506	1,103	2,464	3,379
Loss from operations	(1,468)	(896)	(2,375)	(3,119)
Financial income (expense), net	(5)	(24)	(10)	(51)
Change in fair value of derivative liabilities		107		102
Loss on extinguishment of derivative liability		(288)		(288)
Warrant modification expense				(412)
Loss before taxes on income	(1,473)	(1,101)	(2,385)	(3,768)
Income tax benefit / (expense)	(4)	(6)	(13)	(18)
Net loss	$ (1,477)	$ (1,107)	$ (2,398)	$ (3,786)
Basic and diluted net loss available for holders of common stock, Series C Preferred Stock and Series D Preferred Stock	$ (0.20)	$ (0.16)	$ (0.33)	$ (0.55)
Weighted average common shares outstanding: Basic and diluted	7,252,510	6,788,716	7,279,708	6,841,252

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Series C Preferred Stock [Member]	Series D Preferred Stock [Member]	Series E Preferred Stock [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Total
Beginning balance at Dec. 31, 2018	$ 2			$ 4	$ 32,993	$ (32,536)	$ 463
Beginning balance, shares at Dec. 31, 2018	2,733,142	304		3,801,552
Issuance of common stock as compensation for services					1,042		1,042
Issuance of common stock as compensation for services, shares				275,000
Stock-based compensation					404		404
Exercise of options					4		4
Exercise of options, shares				63,412
Issuance of preferred series E stock			$ 2		3,198		3,200
Issuance of preferred series E stock, shares			1,600,000
Reclassification of warrants					196		196
Warrant modification expense					412		412
Net loss						(3,786)	(3,786)
Ending balance at Jun. 30, 2019	$ 2		$ 2	$ 4	38,249	(36,322)	1,935
Ending balance, shares at Jun. 30, 2019	2,733,142	304	1,600,000	4,139,964
Beginning balance at Mar. 31, 2019	$ 2			$ 4	34,740	(35,215)	(469)
Beginning balance, shares at Mar. 31, 2019	2,733,142	304		3,801,552
Stock-based compensation					111		111
Exercise of options					4		4
Exercise of options, shares				63,412
Issuance of preferred series E stock			$ 2		3,198		3,200
Issuance of preferred series E stock, shares			1,600,000
Reclassification of warrants					196		196
Net loss						(1,107)	(1,107)
Ending balance at Jun. 30, 2019	$ 2		$ 2	$ 4	38,249	(36,322)	1,935
Ending balance, shares at Jun. 30, 2019	2,733,142	304	1,600,000	4,139,964
Beginning balance at Dec. 31, 2019	$ 2		$ 2	$ 5	39,669	(38,330)	1,348
Beginning balance, shares at Dec. 31, 2019	2,993,142	304	1,825,000	4,203,764
Stock-based compensation					143		143
Exchange of Series E Preferred Stock into Common Stock
Exchange of Series E Preferred Stock into Common Stock, shares			(110,000)	110,000
Warrants issued with notes payable					123		123
Net loss						(2,398)	(2,398)
Ending balance at Jun. 30, 2020	$ 2		$ 2	$ 5	39,935	(40,728)	(784)
Ending balance, shares at Jun. 30, 2020	2,993,142	304	1,715,000	4,313,764
Beginning balance at Mar. 31, 2020	$ 2		$ 2	$ 5	39,740	(39,251)	498
Beginning balance, shares at Mar. 31, 2020	2,993,142	304	1,715,000	4,313,764
Stock-based compensation					72		72
Warrants issued with notes payable					123		123
Net loss						(1,477)	(1,477)
Ending balance at Jun. 30, 2020	$ 2		$ 2	$ 5	$ 39,935	$ (40,728)	$ (784)
Ending balance, shares at Jun. 30, 2020	2,993,142	304	1,715,000	4,313,764

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Cash flows from operating activities:
Net loss	$ (2,398)	$ (3,786)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1	2
Stock-based compensation	143	1,446
Noncash interest expense		10
Warrants received as licensing fee	(23)
Change in fair value of equity investment	(9)
Change in fair value of derivative liabilities		(102)
Other expense related to extension of warrants		412
Loss on extinguishment of derivative liability		288
Common stock payable to consultant	844
Changes in operating assets and liabilities:
Trade receivable	(146)	(144)
Other accounts receivable and prepaid expenses	110	(38)
Inventory	(27)	(7)
Trade payables	7	150
Other accounts payable and accrued expenses	(91)	75
Deferred revenue	226
Accrued severance pay, net	(15)	(35)
Net cash used in operating activities	(1,378)	(1,729)
Cash flows from financing activities:
Proceeds from issuance of notes payable to a related party	200
Proceeds from issuance of notes payable	42	475
Payments of convertible notes		(475)
Proceeds from issuance of Preferred Series E stock		3,200
Proceeds from exercise of options		4
Net cash provided by financing activities	242	3,204
Net increase (decrease) in cash, cash equivalents and restricted cash	(1,136)	1,475
Cash, cash equivalents and restricted cash at beginning of period	1,338	896
Cash, cash equivalents and restricted cash at end of period	202	2,371
Supplemental non-cash financing and investing activities:
Cash paid for interest		5
Cash paid for taxes
Discount on notes payable	123
Discount on convertible notes		$ 414

Description of Business

Description of Business	6 Months Ended
	Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	NOTE 1 - DESCRIPTION OF BUSINESS NanoVibronix, Inc. (the “Company”), a Delaware corporation, commenced operations on October 20, 2003 and is a medical device company focusing on noninvasive biological response-activating devices that target wound healing and pain therapy and can be administered at home, without the assistance of medical professionals. The Company’s principal research and development activities are conducted in Israel through its wholly owned subsidiary, NanoVibronix (Israel 2003) Ltd., a company registered in Israel, which commenced operations in October 2003.

Liquidity and Plan of Operation

Liquidity and Plan of Operations	6 Months Ended
	Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Liquidity and Plan of Operations	NOTE 2 - LIQUIDITY AND PLAN OF OPERATIONS The Company’s ability to continue to operate is dependent mainly on its ability to successfully market and sell its products and the receipt of additional financing until profitability is achieved. The Company currently incurs and historically has incurred losses from operations and expects to do so in the foreseeable future. In 2020, the Company raised $200 through the issuance of notes payable from a related party and received $42 from the Paycheck Protection Program. Despite the recent financing, the Company will not have sufficient resources to fund its operations for the next twelve months from the date of this filing. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. During the next twelve months management expects that the Company will need to raise additional capital to finance its losses and negative cash flows from operations and may continue to be dependent on additional capital raising as long as its products do not reach commercial profitability. In connection with the lawsuit filed by the Company’s former officer and director in the Haifa Israel District Financial Court, the Company was required by the court to keep $350,000 of cash restricted. See Note 10 – Commitments and Contingencies – Legal Proceedings. Subsequent to the imposition of this requirement, the Company failed to maintain a sufficient amount of cash to comply with the court order. As of June 30, 2020, there was no event of default or violation of a covenant in outstanding notes resulting from the breach of the court order. Management’s plans include the continued commercialization of the Company’s products and raising capital through the sale of additional equity securities, debt or capital inflows from strategic partnerships. There are no assurances, however, that the Company will be successful in obtaining the level of financing needed for its operations. If the Company is unsuccessful in commercializing its products and raising capital, it will need to reduce activities, curtail or cease operations. The financial statements do not include any adjustments with respect to the carrying amounts of assets and liabilities and their classification that might be necessary should the Company be unable to continue as a going concern.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of presentation and principles of consolidation The Company’s condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) for the interim financial information and with instructions to Form 10-Q and Article 10 of Regulation S-X. The unaudited consolidated financial statements include the accounts of all subsidiaries in which the Company holds a controlling financial interest as of the financial statement date. The unaudited consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. The terms “we,” “us,” “our,” and the “Company” refer to NanoVibronix, Inc. and its wholly owned subsidiary. All intercompany accounts and transactions have been eliminated in consolidation. Unaudited interim financial information In the opinion of management, the accompanying unaudited interim consolidated financial statements reflect all adjustments, which include only normal recurring adjustments, necessary to state fairly the financial position and results of operations of the Company. These consolidated financial statements and notes thereto are unaudited and should be read in conjunction with the Company’s audited financial statements for the year ended December 31,2019, as found in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on May 20, 2020. The balance sheet for December 31, 2019 was derived from the Company’s audited financial statements for the year ended December 31, 2019. The results of operations for the periods presented are not necessarily indicative of results that could be expected for the entire fiscal year due to seasonality and other factors. Certain information and footnote disclosures normally included in the consolidated financial statements in accordance with U.S. GAAP have been omitted in accordance with the rules and regulations of the SEC for interim reporting. Use of estimates The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions. The Company believe that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Cash and cash equivalents Cash consists of funds on hand and held in bank accounts. Cash equivalents includes demand deposits placed with banks or other financial institutions and all highly liquid investments with original maturities of three months or less. Restricted cash of $202 represents cash restricted per a court order which resulted from a dispute between the Company and a former officer and director, see Note 10. Foreign currency translation and transaction Non-U.S. dollar denominated transactions and balances have been re-measured to U.S. dollars. All transaction gains and losses from re-measurement of monetary balance sheet items denominated in non-U.S. dollar currencies are reflected in the statements of operations as financial income or expenses, as appropriate. Gains and losses from foreign currency translation for the six months ended June 30, 2020 and 2019 were $6 and $28, respectively. Revenue recognition It is the Company’s policy that revenues from product sales is recognized in accordance with ASC 606 “Revenue Recognition.” Five basic steps must be followed before revenue can be recognized; (1) Identifying the contract(s) with a customer that creates enforceable rights and obligations; (2) Identifying the performance obligations in the contract, such as promising to transfer goods or services to a customer; (3) Determining the transaction price, meaning the amount of consideration in a contract to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer; (4) Allocating the transaction price to the performance obligations in the contract, which requires the company to allocate the transaction price to each performance obligation on the basis of the relative standalone selling prices of each distinct good or services promised in the contract; and (5) Recognizing revenue when (or as) the entity satisfies a performance obligation by transferring a promised good or service to a customer. The amount of revenue recognized is the amount allocated to the satisfied performance obligation. Adoption of ASC 606 has not changed the timing and nature of the Company’s revenue recognition and there has been no material effect on the Company’s financial statements. Revenue from product sales is recorded at the net sales price, or “transaction price,” which includes estimates of variable consideration that result from coupons, discounts, chargebacks and distributor fees, processing fees, as well as allowances for returns and government rebates. The Company constrains revenue by giving consideration to factors that could otherwise lead to a probable reversal of revenue. Collectability of revenue is reasonably assured based on historical evidence of collectability between the Company and its customers. See Note 7 for a detailed breakout of revenue. Revenues from sales to distributors are recognized at the time the products are delivered to the distributors (“sell-in”). The Company does not grant rights of return, credits, rebates, price protection, or other privileges on its products to distributors. Fair Value Measurements When required to measure assets or liabilities at fair value, the Company uses a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used. The Company determines the level within the fair value hierarchy in which the fair value measurements in their entirety fall. The categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Level 1 uses quoted prices in active markets for identical assets or liabilities, Level 2 uses significant other observable inputs, and Level 3 uses significant unobservable inputs. The amount of the total gains or losses for the period are included in earnings that are attributable to the change in unrealized gains or losses relating to those assets and liabilities still held at the reporting date. We measure our investment in equity securities at fair value on a recurring basis. The Company’s equity securities are valued using inputs observable in active markets and are therefore classified as Level 1 within the fair value hierarchy. Recently issued accounting pronouncements not yet adopted In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). ASU 2016-02 requires that a lessee recognize the assets and liabilities that arise from operating leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right of use asset representing its right to use the underlying asset for the lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. Public business entities should apply the amendments in ASU 2016-02 for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted for all public business entities and all nonpublic business entities upon issuance. The Company (as an EGC) that is taking advantage of the extended transition period offered to private entities would apply this for fiscal years beginning after December 15, 2021. The Company does not believe that the adoption will have a material effect on the Company’s condensed interim consolidated financial statements and related disclosures. In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”) and also issued subsequent amendments to the initial guidance: ASU 2018-19, ASU 2019-04, and ASU 2019-05 (collectively, “Topic 326”). Topic 326 requires measurement and recognition of expected credit losses for financial assets held. The Company will be required to adopt this ASU for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The adoption of Topic 326 is not expected to have a material on the Company’s financial statements and financial statement disclosures. Recently adopted accounting standards In August 2018, the FASB issued ASU 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement”, which adds disclosure requirements to Topic 820 for the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. This ASU is effective for interim and annual reporting periods beginning after December 15, 2019. Although the Company adopted ASU 2018-13 on January 1, 2020, there was no material impact on the financial statements.

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2020
Equity [Abstract]
Stockholders' Equity	NOTE 4 - STOCKHOLDERS’ EQUITY Stock-based compensation and Options During the six-month period ended June 30, 2020 and 2019, 15,000 and 120,000 options were granted, respectively. The options granted in 2020 were to a non-employee and were recorded at a fair value of $14 and vest quarterly over 12 months. The options granted in 2019 were to a non-employee and were recorded at a fair value of $183 and vested immediately. During the three and six-month period ended June 30, 2020, there was stock-based compensation expense of $72 and $143, respectively. During the three and six-month period ended June 30, 2019, there was stock-based compensation expense of $111 and $1,446, respectively. The fair value for options granted in the 2020 is estimated at the date of grant using a Black-Scholes-Merton options pricing model with the following underlying assumptions: Price at valuation $ 1.86 Exercise price $ 1.86 Risk free interest 0.34 % Expected term (in years) 5 Volatility 60.2 % The total stock-based expense recognized in the financial statements for services received from employees and non-employees is shown in the following table. Three Months Ended Six Months Ended June 30, June 30, 2020 2019 2020 2019 Research and development 1 - 1 - Selling and marketing 11 11 22 22 General and administrative 60 100 120 1,424 Total $ 72 $ 111 $ 143 $ 1,446 As of June 30, 2020, the total unrecognized estimated compensation cost related to non-vested stock options granted prior to that date was $122, which is expected to be recognized over a weighted average period of approximately 0.62 years. Series E Preferred Stock conversion to common stock Each share of Series E Preferred Stock is convertible at any time and from time to time at the option of a holder of Series E Preferred Stock into one share of the Company’s common stock, provided that each holder would be prohibited from converting Series E Preferred Stock into shares of the Company’s common stock if, as a result of such conversion, any such holder, together with its affiliates, would own more than 9.99% of the total number of shares of the Company’s common stock then issued and outstanding. This limitation may be waived with respect to a holder upon such holder’s provision of not less than 61 days’ prior written notice to the Company. In February 2020, a shareholder converted 110,000 shares of Series E Preferred Stock into 110,000 shares of common stock at a conversion rate of 1 to 1. No purchase was made in order to convert these shares.

Notes Payable

Notes Payable	6 Months Ended
	Jun. 30, 2020
Debt Disclosure [Abstract]
Notes Payable	NOTE 5 – NOTES PAYABLE In May 2020, the Company was granted a loan (the “PPP Loan”) in the amount of $42, pursuant to the Paycheck Protection Program (the “PPP”) under Division A, Title I of the Coronavirus Aid, Relief, and Economic Securities (“CARES”) Act, which was enacted March 27, 2020. The application for these funds required the Company to, in good faith, certify that the current economic uncertainty made the loan request necessary to support the ongoing operations of the Company. This certification further required the Company to consider its current business activity and its ability to access other sources of liquidity sufficient to support ongoing operations in a manner that is not significantly detrimental to the business. The Company made this good faith assertion based upon the adverse impact the COVID-19 pandemic had on its business and the global economy. While the Company has made this assertion in good faith based upon all available guidance, management will continue to assess their continued qualification if and when updated guidance is released by the Treasury Department. The receipt of these funds, and the forgiveness of the loan attendant to these funds, is dependent on the Company having initially qualified for the loan and qualifying for the forgiveness of such loan based on its future adherence to the forgiveness criteria. The PPP Loan, which was in the form of a note that was granted on May 14, 2020, matures in two years and accrues interest at a rate of 1.00% per annum, payable in monthly payments commencing six months after loan disbursement. The Company also has the option to negotiate with the lender to extend the maturity date to up to five years. The note may be prepaid by the Company at any time prior to maturity with no prepayment penalties. Funds from the PPP Loan may only be used for payroll costs and any payments of certain covered interest, lease and utility payments. The Company intends to use the entire PPP Loan amount for qualifying expenses. Under the terms of the PPP, certain amounts of the Loan may be forgiven if they are used for qualifying expenses as described in the CARES Act. The ultimate forgiveness of the PPP Loan is also predicated upon regulatory authorities concurring with management’s good faith assessment that the current economic uncertainty made the loan request necessary to support ongoing operations. If, despite the Company’s good-faith belief that given the circumstances the Company satisfied all eligibility requirements for the PPP Loan, the Company is later determined to have violated any applicable laws or regulations or it is otherwise determined that the Company was ineligible to receive the PPP Loan, the Company may be required to repay the PPP Loan in its entirety and/or be subject to additional penalties. In the event the PPP Loan, or any portion thereof, is forgiven, the amount forgiven is applied to outstanding principal On June 22, 2020, the Company issued and sold to a related party an unsecured promissory note in the principal amount of $200, which accrues interest at 10% per annum and matures in one year. In addition to the promissory note, the Company granted a seven-year equity warrant to purchase 100,000 shares of the Company’s common stock. The exercise price for each warrant share is equal to $2.50, and the warrants may also be exercised, in whole or in part, by means of a cashless exercise. The warrants were recognized as a debt discount and is amortized over the life of the note. The warrants were valued at $123 using a Black Scholes Merton pricing model with the following underlying assumptions: Price at valuation $ 2.21 Exercise price $ 2.50 Risk free interest 0.34 % Expected term (in years) 7 Volatility 60.7 % In connection with the lawsuit filed by the Company’s former officer and director in the Haifa Israel District Financial Court, the Company was required by the court to keep $350,000 of cash restricted. See Note 10 – Commitments and Contingencies – Legal Proceedings. Subsequent to the imposition of this requirement, the Company failed to maintain a sufficient amount of cash to comply with the court order. As of June 30, 2020, there was no event of default or violation of a covenant in outstanding notes resulting from the breach of the court order.

Loss Per Share Applicable to Co

Loss Per Share Applicable to Common Stockholder	6 Months Ended
	Jun. 30, 2020
Earnings Per Share [Abstract]
Loss Per Share Applicable to Common Stockholder	NOTE 6 - LOSS PER SHARE APPLICABLE TO COMMON STOCKHOLDER Basic net loss per common share (“Basic EPS”) is computed by dividing net loss available to common stockholders by the weighted average number of shares of common stock outstanding during the period. All outstanding stock options and warrants for the three and six months ended June 30, 2020 and 2019 have been excluded from the calculation of the diluted net loss per share because all such securities are anti-dilutive for all periods presented. The following table summarizes the Company’s securities, in common stock equivalents, which have been excluded from the calculation of dilutive loss per share as their effect would be anti-dilutive: June 30, 2020 June 30, 2019 Series D Preferred Stock 303,782 303,782 Series E Preferred Stock 1,715,000 1,600,000 Stock Options - employee and non-employee 1,571,332 749,361 Warrants 266,667 266,667 Total 3,856,781 2,919,810

Geographic Information and Majo

Geographic Information and Major Customer Data	6 Months Ended
	Jun. 30, 2020
Segment Reporting [Abstract]
Geographic Information and Major Customer Data	NOTE 7 - GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER DATA Summary information about geographic areas: The Company manages its business on the basis of one reportable segment and derives revenues from selling its products directly to patients as well as through distributor and licensing agreements. The following is a summary of revenues within geographic areas: Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 United States $ 151 $ 90 $ 261 $ 158 Europe 117 151 120 161 Israel 1 12 2 13 India - 8 - 8 Canada - 2 - 2 Total $ 269 $ 263 $ 383 $ 342 During the three-month period ended June 30, 2020 and 2019, revenues from distributors accounted for 88% and 40% of total revenues, respectively. During the six-month period ended June 30, 2020 and 2019, revenues from distributors accounted for 91% and 50% of total revenues, respectively.

Other Assets

Other Assets	6 Months Ended
	Jun. 30, 2020
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Other Assets	NOTE 8 – OTHER ASSETS On April 9, 2020, pursuant to a licensing agreement entered into in March 2020, the Company received 10-year warrants to purchase 127,000 shares of Sanuwave Health, Inc. at a price of $0.19 per share. The fair value for warrants received is estimated at the date of grant using a Black-Scholes-Merton pricing model with the following underlying assumptions: Price at valuation $ 0.19 – 0.26 Exercise price $ 0.19 Risk free interest 0.66 - 0.73 % Expected term (in years) 10 Volatility 140.6 – 142.3 % We consider this to be level 3 inputs and is valued at each reporting period. The fair value of these warrants on April 9, 2020 and June 30, 2020 was $23 and $32, respectively. The change in fair value for the six months ended June 30, 2020 was $9.

Common Stock Payable

Common Stock Payable	6 Months Ended
	Jun. 30, 2020
Common Stock Payable
Common Stock Payable	NOTE 9 – COMMON STOCK PAYABLE On February 11, 2019, the Company entered into a consulting agreement (the “Agreement”) with Bespoke Growth Partners, Inc. (“Bespoke”), pursuant to which, amongst other things, Bespoke was entitled to receive up to 650,000 shares of common stock of the Company, of which 275,000 shares were issued on the date of signing. On August 5, 2020, the Company paid $75 and issued an additional 375,000 shares of common stock to Bespoke under the Agreement. Such issuance was undertaken in reliance upon the exemption from the registration requirements of the Securities Act of 1933, as amended, pursuant to Section 4(a)(2) thereof and Rule 506 of Regulation D promulgated thereunder. As of June 30, 2020, 375,000 shares of common stock, valued at $2.25 per share, or $844, was owed to Bespoke.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 10 - COMMITMENTS AND CONTINGENCIES Leases The Company leases office facilities and motor vehicles under operating leases, which expire on various dates, the latest of which is 2020. Rent and related expenses were $13 and $25, for the three and six months ended June 30, 2020, respectively, and $15 and $27 for the three and six months ended June 30, 2019, respectively. Other Risks On March 12, 2020, the World Health Organization declared COVID-19 to be a pandemic, and the COVID-19 pandemic has resulted in significant financial market volatility and uncertainty. A continuation or worsening of the levels of market disruption and volatility seen in the recent past could have an adverse effect on our ability to access capital, on our business, results of operations and financial condition, and on the market price of our common shares. On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. In addition, the CARES Act allows NOLs incurred in 2018, 2019, and 2020 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes. The Company has been consistently in a loss position in the U.S. and at present does not expect that the NOL carryback provision of the CARES Act would result in a material cash benefit to the Company. In June 2020, the Company experienced a cybersecurity incident. Specifically, the Company believes that one or two unauthorized third parties were able to use an email domain similar to the Company’s to convince two of the Company’s customers to send payments in the aggregate amount of approximately $308 to unauthorized bank accounts that should have been sent to the Company. The total amount of customer payments has been recovered and received by the Company. Legal Proceedings We are subject to a lawsuit filed by our former officer and director, Jona Zumeris, on December 17, 2019 in the Haifa Israel District Financial Court, seeking damages of approximately $900,000 for breach of the Separation Agreement executed on July 4, 2018, and to which matter both parties have agreed to proceed to settle in mediation scheduled to begin in late May 2020. We believe that a major part of the allegations included in the suit are without merit, however, due to the uncertainties of litigation or mediation, we can give no assurance that we will be able to reach reasonable settlement, or if it were to proceed in court, prevail on the claims made against us in such lawsuit. The Israeli court issued a court order demanding that we restrict approximately $700,000 of the Company’s money until the matter is adjudicated. The Company appealed the court order. In February 2020, the Company agreed to restrict approximately $350,000 and agreed to try to settle the matter in mediation which commenced in May 2020. The cash restriction is relating to this dispute is reflected on the balance sheet as “restricted cash.” The court required such amount restricted and separated in the Company’s bank savings account; however, the Company’s bank accounts do not have any restrictions in place which prohibit the Company from using its available funds at its discretion. The Company did not have sufficient amount of cash to comply with the court order and only had restricted cash of $202,000 in its bank account as of June 30, 2020. Following June 30, 2020, the Company has used its available funds, including most of the restricted cash, in order to fund its operations. A settlement was not reached in May and although the mediation process has not yet concluded, the Company believes that it and will now likely go to trial, although no date has been set.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2020
Subsequent Events [Abstract]
Subsequent Events	NOTE 11 - SUBSEQUENT EVENTS In July 2020, the Company granted 122,000 options to board members and 50,000 options to a non-employee consultant. On July 7, 2020, a shareholder converted 300,000 shares of Series E Preferred Stock into 300,000 shares of common stock at a conversion rate of 1 to 1. No purchase was made in order to convert these shares. On September 14, 2018, the Company received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it was no longer in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires listed companies to maintain stockholders’ equity of at least $2.5 million (the “Equity Requirement”). Following a hearing on May 2, 2019, a Nasdaq Hearings Panel was appointed to review the Company’s compliance with the Equity Requirement, and on August 5, 2020, the Staff issued a letter to the Company in which it indicated that, since the Company had failed to report stockholders’ equity of at least $2.5 million in each of its last three periodic reports filed with the Securities and Exchange Commission, its common shares would be subject to delisting on August 14, 2020, unless the Company requests an appeal of this determination by 4:00 p.m. Eastern Time on August 12, 2020 (the “Hearing Request”). The Company submitted a Hearing Request on August 12, 2020 and a hearing has been scheduled for September 10, 2020. The Hearing Request will automatically stay any suspension or delisting action pending a decision of a Nasdaq Hearings Panel. At the hearing, the Company will provide the Nasdaq Hearings Panel with an update on its compliance plan and, if necessary, request a further extension of time in which to regain compliance. Pursuant to the Nasdaq Listing Rules, the Nasdaq Hearings Panel has the discretion to grant an additional extension of time of up to 180 calendar days, as measured from August 5, 2020. There can be no assurance that the Company’s plan will be accepted by the Nasdaq Hearings Panel or that, if it is, the Company will be able to regain compliance with the applicable Nasdaq listing requirements. If the Company’s common stock is delisted, it could be more difficult to buy or sell the Company’s common stock or to obtain accurate quotations, and the price of the Company’s common stock could suffer a material decline. Delisting could also impair the Company’s ability to raise capital.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of presentation and principles of consolidation The Company’s condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) for the interim financial information and with instructions to Form 10-Q and Article 10 of Regulation S-X. The unaudited consolidated financial statements include the accounts of all subsidiaries in which the Company holds a controlling financial interest as of the financial statement date. The unaudited consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. The terms “we,” “us,” “our,” and the “Company” refer to NanoVibronix, Inc. and its wholly owned subsidiary. All intercompany accounts and transactions have been eliminated in consolidation.
Unaudited Interim Financial Information	Unaudited interim financial information In the opinion of management, the accompanying unaudited interim consolidated financial statements reflect all adjustments, which include only normal recurring adjustments, necessary to state fairly the financial position and results of operations of the Company. These consolidated financial statements and notes thereto are unaudited and should be read in conjunction with the Company’s audited financial statements for the year ended December 31,2019, as found in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on May 20, 2020. The balance sheet for December 31, 2019 was derived from the Company’s audited financial statements for the year ended December 31, 2019. The results of operations for the periods presented are not necessarily indicative of results that could be expected for the entire fiscal year due to seasonality and other factors. Certain information and footnote disclosures normally included in the consolidated financial statements in accordance with U.S. GAAP have been omitted in accordance with the rules and regulations of the SEC for interim reporting.
Use of Estimates	Use of estimates The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions. The Company believe that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents	Cash and cash equivalents Cash consists of funds on hand and held in bank accounts. Cash equivalents includes demand deposits placed with banks or other financial institutions and all highly liquid investments with original maturities of three months or less. Restricted cash of $202 represents cash restricted per a court order which resulted from a dispute between the Company and a former officer and director, see Note 10.
Foreign Currency Translation and Transaction
Revenue Recognition	Revenue recognition It is the Company’s policy that revenues from product sales is recognized in accordance with ASC 606 “Revenue Recognition.” Five basic steps must be followed before revenue can be recognized; (1) Identifying the contract(s) with a customer that creates enforceable rights and obligations; (2) Identifying the performance obligations in the contract, such as promising to transfer goods or services to a customer; (3) Determining the transaction price, meaning the amount of consideration in a contract to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer; (4) Allocating the transaction price to the performance obligations in the contract, which requires the company to allocate the transaction price to each performance obligation on the basis of the relative standalone selling prices of each distinct good or services promised in the contract; and (5) Recognizing revenue when (or as) the entity satisfies a performance obligation by transferring a promised good or service to a customer. The amount of revenue recognized is the amount allocated to the satisfied performance obligation. Adoption of ASC 606 has not changed the timing and nature of the Company’s revenue recognition and there has been no material effect on the Company’s financial statements. Revenue from product sales is recorded at the net sales price, or “transaction price,” which includes estimates of variable consideration that result from coupons, discounts, chargebacks and distributor fees, processing fees, as well as allowances for returns and government rebates. The Company constrains revenue by giving consideration to factors that could otherwise lead to a probable reversal of revenue. Collectability of revenue is reasonably assured based on historical evidence of collectability between the Company and its customers. See Note 7 for a detailed breakout of revenue. Revenues from sales to distributors are recognized at the time the products are delivered to the distributors (“sell-in”). The Company does not grant rights of return, credits, rebates, price protection, or other privileges on its products to distributors.
Fair Value Measurements	Fair Value Measurements When required to measure assets or liabilities at fair value, the Company uses a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used. The Company determines the level within the fair value hierarchy in which the fair value measurements in their entirety fall. The categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Level 1 uses quoted prices in active markets for identical assets or liabilities, Level 2 uses significant other observable inputs, and Level 3 uses significant unobservable inputs. The amount of the total gains or losses for the period are included in earnings that are attributable to the change in unrealized gains or losses relating to those assets and liabilities still held at the reporting date. We measure our investment in equity securities at fair value on a recurring basis. The Company’s equity securities are valued using inputs observable in active markets and are therefore classified as Level 1 within the fair value hierarchy.
Recently Issued Accounting Pronouncements Not Yet Adopted	Recently issued accounting pronouncements not yet adopted In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). ASU 2016-02 requires that a lessee recognize the assets and liabilities that arise from operating leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right of use asset representing its right to use the underlying asset for the lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. Public business entities should apply the amendments in ASU 2016-02 for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted for all public business entities and all nonpublic business entities upon issuance. The Company (as an EGC) that is taking advantage of the extended transition period offered to private entities would apply this for fiscal years beginning after December 15, 2021. The Company does not believe that the adoption will have a material effect on the Company’s condensed interim consolidated financial statements and related disclosures. In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”) and also issued subsequent amendments to the initial guidance: ASU 2018-19, ASU 2019-04, and ASU 2019-05 (collectively, “Topic 326”). Topic 326 requires measurement and recognition of expected credit losses for financial assets held. The Company will be required to adopt this ASU for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The adoption of Topic 326 is not expected to have a material on the Company’s financial statements and financial statement disclosures.
Recently Adopted Accounting Standards	Recently adopted accounting standards In August 2018, the FASB issued ASU 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement”, which adds disclosure requirements to Topic 820 for the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements. This ASU is effective for interim and annual reporting periods beginning after December 15, 2019. Although the Company adopted ASU 2018-13 on January 1, 2020, there was no material impact on the financial statements.

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2020
Equity [Abstract]
Schedule of Fair Value Assumptions for Options Granted	The fair value for options granted in the 2020 is estimated at the date of grant using a Black-Scholes-Merton options pricing model with the following underlying assumptions: Price at valuation $ 1.86 Exercise price $ 1.86 Risk free interest 0.34 % Expected term (in years) 5 Volatility 60.2 %
Schedule of Stock Based Expenses Recognized for Services from Employees and Non-Employees	The total stock-based expense recognized in the financial statements for services received from employees and non-employees is shown in the following table. Three Months Ended Six Months Ended June 30, June 30, 2020 2019 2020 2019 Research and development 1 - 1 - Selling and marketing 11 11 22 22 General and administrative 60 100 120 1,424 Total $ 72 $ 111 $ 143 $ 1,446

Notes Payable (Tables)

Notes Payable (Tables)	6 Months Ended
	Jun. 30, 2020
Debt Disclosure [Abstract]
Schedule of Warrants Assumptions	The warrants were valued at $123 using a Black Scholes Merton pricing model with the following underlying assumptions: Price at valuation $ 2.21 Exercise price $ 2.50 Risk free interest 0.34 % Expected term (in years) 7 Volatility 60.7 %

Loss Per Share Applicable to _2

Loss Per Share Applicable to Common Stockholder (Tables)	6 Months Ended
	Jun. 30, 2020
Earnings Per Share [Abstract]
Summary of Common Share Equivalents Been Excluded from Dilutive Loss Per Share as Anti-dilutive	The following table summarizes the Company’s securities, in common stock equivalents, which have been excluded from the calculation of dilutive loss per share as their effect would be anti-dilutive: June 30, 2020 June 30, 2019 Series D Preferred Stock 303,782 303,782 Series E Preferred Stock 1,715,000 1,600,000 Stock Options - employee and non-employee 1,571,332 749,361 Warrants 266,667 266,667 Total 3,856,781 2,919,810

Geographic Information and Ma_2

Geographic Information and Major Customer Data (Tables)	6 Months Ended
	Jun. 30, 2020
Segment Reporting [Abstract]
Summary of Revenue within Geographic Areas	The Company manages its business on the basis of one reportable segment and derives revenues from selling its products directly to patients as well as through distributor and licensing agreements. The following is a summary of revenues within geographic areas: Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 United States $ 151 $ 90 $ 261 $ 158 Europe 117 151 120 161 Israel 1 12 2 13 India - 8 - 8 Canada - 2 - 2 Total $ 269 $ 263 $ 383 $ 342

Other Assets (Tables)

Other Assets (Tables)	6 Months Ended
	Jun. 30, 2020
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of Warrants Assumtions	The fair value for warrants received is estimated at the date of grant using a Black-Scholes-Merton pricing model with the following underlying assumptions: Price at valuation $ 0.19 – 0.26 Exercise price $ 0.19 Risk free interest 0.66 - 0.73 % Expected term (in years) 10 Volatility 140.6 – 142.3 %

Liquidity and Plan of Operati_2

Liquidity and Plan of Operations (Details Narrative) - USD ($) $ in Thousands	1 Months Ended	6 Months Ended
	May 31, 2020	Jun. 30, 2020	Jun. 30, 2019
Proceeds from issuance of notes payable from a related party		$ 200
Restricted cash		350,000
Paycheck Protection Program [Member]
Proceeds from issuances of debt	$ 42	$ 42

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details Narrative) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Accounting Policies [Abstract]
Restricted cash	$ 202
Gains and losses from foreign currency translation	$ 6	$ 28

Stockholders' Equity (Details N

Stockholders' Equity (Details Narrative) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		6 Months Ended
	Feb. 29, 2020	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Number of options, granted				15,000	120,000
Stock-based compensation expense		$ 72	$ 111	$ 143	$ 1,446
Non-vested stock options granted, unrecognized estimated compensation cost		$ 122		$ 122
Fair value options vesting term				7 months 13 days
Conversion description	Conversion rate of 1 to 1
Series E Preferred Stock [Member]
Preferred stock, conversion description				Each share of Series E Preferred Stock is convertible at any time and from time to time at the option of a holder of Series E Preferred Stock into one share of the Company's common stock, provided that each holder would be prohibited from converting Series E Preferred Stock into shares of the Company's common stock if, as a result of such conversion, any such holder, together with its affiliates, would own more than 9.99% of the total number of shares of the Company's common stock then issued and outstanding. This limitation may be waived with respect to a holder upon such holder's provision of not less than 61 days' prior written notice to the Company.
Number of shares issued for conversion	110,000
Common Stock [Member]
Number of shares issued for conversion	110,000
Non-Employee [Member]
Fair value of options, vested				$ 14	$ 183

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Fair Value Assumptions for Options Granted (Details)	6 Months Ended
	Jun. 30, 2020$ / shares
Equity [Abstract]
Price at valuation	$ 1.86
Exercise price	$ 1.86
Risk free interest	0.34%
Expected term (in years)	5 years
Volatility	60.20%

Stockholders' Equity - Schedu_2

Stockholders' Equity - Schedule of Stock Based Expenses Recognized for Services from Employees and Non-Employees (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation	$ 72	$ 111	$ 143	$ 1,446
Research and Development Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation	1		1
Selling and Marketing [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation	11	11	22	22
General and Administrative [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation	$ 60	$ 100	$ 120	$ 1,424

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	May 14, 2020	May 31, 2020	Jun. 30, 2020	Jun. 22, 2020	Apr. 09, 2020
Warrants term			7 years		10 years
Restricted cash			$ 350,000
Paycheck Protection Program [Member]
Proceeds from issuances of debt		$ 42	$ 42
Debt instrument term	2 years
Debt interest rate	1.00%
Unsecured Promissory Note [Member]
Debt instrument principal amount				$ 200
Warrants term				7 years
Warrants purchase to common stock				100,000
Warrants exercise				$ 2.50
Warrants purchase to common stock, value				123

Notes Payable - Schedule of War

Notes Payable - Schedule of Warrants Assumptions (Details)	Jun. 30, 2020$ / shares	Apr. 09, 2020
Price at valuation	$ 2.21
Exercise price	$ 2.50
Warrants term	7 years	10 years
Risk Free Interest [Member]
Warrants measurement input	0.34
Volatility [Member]
Warrants measurement input	60.7

Loss Per Share Applicable to _3

Loss Per Share Applicable to Common Stockholder - Summary of Common Share Equivalents Been Excluded from Dilutive Loss Per Share as Anti-dilutive (Details) - shares	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Total	3,856,781	2,919,810
Series D Preferred Stock [Member]
Total	303,782	303,782
Series E Preferred Stock [Member]
Total	1,715,000	1,600,000
Stock Options - Employee and Non-Employee [Member]
Total	1,571,332	749,361
Warrants [Member]
Total	266,667	266,667

Geographic Information and Ma_3

Geographic Information and Major Customer Data (Details Narrative) - segment	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Number of reportable segments			1
Sales Revenue [Member]
Concentration risk, percentage	88.00%	40.00%	91.00%	50.00%

Geographic Information and Ma_4

Geographic Information and Major Customer Data - Summary of Revenue within Geographic Areas (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Revenues	$ 269	$ 263	$ 383	$ 342
United States [Member]
Revenues	151	90	261	158
Europe [Member]
Revenues	117	151	120	161
Israel [Member]
Revenues	1	12	2	13
India [Member]
Revenues		8		8
Canada [Member]
Revenues		$ 2		$ 2

Other Assets (Details Narrative

Other Assets (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	Apr. 09, 2020	Jun. 30, 2020
Fair value of warrants	$ 23	$ 32
Change in fair value of warrants		$ 9
Licensing Agreement [Member]
Warrant term	10 years
Licensing Agreement [Member] | Sanuwave Health, Inc. [Member]
Warrant to purchase shares	127,000
Warrant exercise price	$ 0.19

Other Assets - Schedule of Warr

Other Assets - Schedule of Warrants Assumtions (Details)	Jun. 30, 2020	Apr. 09, 2020segment
Expected term (in years)	7 years	10 years
Price At Valuation [Member] | Minimum [Member]
Warrants and rights outstanding, measurement input		0.19
Price At Valuation [Member] | Maximum [Member]
Warrants and rights outstanding, measurement input		0.26
Exercise Price [Member]
Warrants and rights outstanding, measurement input		0.19
Risk Free Interest [Member]
Warrants and rights outstanding, measurement input	0.34
Risk Free Interest [Member] | Minimum [Member]
Warrants and rights outstanding, measurement input		0.66
Risk Free Interest [Member] | Maximum [Member]
Warrants and rights outstanding, measurement input		0.73
Volatility [Member]
Warrants and rights outstanding, measurement input	60.7
Volatility [Member] | Minimum [Member]
Warrants and rights outstanding, measurement input		140.6
Volatility [Member] | Maximum [Member]
Warrants and rights outstanding, measurement input		142.3

Common Stock Payable (Details N

Common Stock Payable (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	Aug. 05, 2020	Feb. 11, 2019	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Number of common stock shares value issued			$ 3,200		$ 3,200
Consulting Agreement [Member] | Subsequent Event [Member]
Number of common stock shares were issued	375,000
Common stock were paid	$ 75
Consulting Agreement [Member] | Bespoke Growth Partners, Inc. [Member]
Received shares of common stock		650,000
Number of common stock shares were issued		275,000		375,000
Share issued price				$ 2.25
Number of common stock shares value issued				$ 844

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($) $ in Thousands	Mar. 27, 2020	Dec. 17, 2019	Jun. 30, 2020	Feb. 29, 2020	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Rent and related expenses					$ 13	$ 15	$ 25	$ 27
Income tax, description	The CARES Act, among other things, permits NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021
Payments to unauthorized bank accounts			$ 308
Restricted cash			$ 202		$ 202		$ 202
Jona Zumeris [Member]
Litigation damages sought value		$ 900
Former Officer [Member]
Litigation damages sought value		$ 700
Litigation settlement, amount				$ 350

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - shares	Aug. 05, 2020	Jul. 07, 2020	Sep. 14, 2018	Jul. 31, 2020	Feb. 29, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Number of option granted to purchase common stock							15,000	120,000
Description of maintenance of stockholder's equity requirement			The Company received a letter from the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it was no longer in compliance with the minimum stockholders' equity requirement for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires listed companies to maintain stockholders' equity of at least $2.5 million (the "Equity Requirement").
Common Stock [Member]
Number of common stock shares were issued
Series E Preferred Stock [Member]
Number of shares converted of common stock					110,000
Number of common stock shares were issued						1,600,000		1,600,000
Subsequent Event [Member]
Description of maintenance of stockholder's equity requirement	The Staff issued a letter to the Company in which it indicated that, since the Company had failed to report stockholders' equity of at least $2.5 million in each of its last three periodic reports filed with the Securities and Exchange Commission, its common shares would be subject to delisting on August 14, 2020, unless the Company requests an appeal of this determination by 4:00 p.m. Eastern Time on August 12, 2020 (the "Hearing Request").
Subsequent Event [Member] | Common Stock [Member]
Number of shares converted of common stock		300,000
Subsequent Event [Member] | Series E Preferred Stock [Member]
Number of shares converted of preferred stock		300,000
Subsequent Event [Member] | Board Members [Member]
Number of option granted to purchase common stock				122,000
Subsequent Event [Member] | Non-employee Consultant [Member]
Number of option granted to purchase common stock				50,000